External Institutional Review Boards
If you’re interested in enlisting the services of an external institutional review board (IRB), whether commercial or academic, please contact NYU Langone’s External Review Unit at firstname.lastname@example.org.
If you are receiving federal funding for a multisite study that requires the use of a single IRB (sIRB), and if NYU Grossman School of Medicine is the main site, please contact email@example.com for information regarding sIRB. Learn more about using the NYU Grossman School of Medicine IRB as the sIRB of your study (Kerberos ID and password required).
Use of external IRBs is only permitted if your plan to use an external IRB has been cleared by the NYU Langone External Review Unit and:
- Your study is industry initiated and using an external IRB that we have a relationship with (see next section)
- Your study is a federally sponsored, multicenter trial that requires the use of an sIRB
Exceptions are considered on a case-by-case basis.
Learn more about the process:
- Using an External IRB
- Initial Study Submission Requirements and Principal Investigator Responsibilities
- Continuing Review, Study Modifications, and Study Closures
NYU Grossman School of Medicine has relationships with the following external IRBs, all of which are accredited by the Association for the Accreditation of Human Research Protection Programs (AAHRPP):
- the Biomedical Research Alliance of New York Institutional Review Board (BRANY IRB)
- the Western Institutional Review Board (WIRB)
- the Central Institutional Review Board for the National Cancer Institute (NCI CIRB)
We also participate in SMART IRB, an initiative that streamlines the IRB reliance process for multisite studies.
If you’re interested in enlisting the services of an external IRB, whether commercial or academic, please contact NYU Langone’s External Review Unit at firstname.lastname@example.org.
If you would like to consider using an external IRB for a cancer clinical trial, email Jennifer Tiao, assistant research regulatory manager of the Perlmutter Cancer Center Clinical Trials Office Regulatory Affairs Unit, at email@example.com.
Before submitting new studies to an external IRB, principal investigators are required to obtain institutional clearance from the External Review Unit before any research activities can begin. This is done by submitting the new study within Research Navigator for institutional tracking and documentation purposes.
Please complete the following procedural steps outlined within the Study Team Guidance Checklist for Institutional Clearance Review for External IRB Submissions.
Click here to view the Research Navigator Initial Submission Guide for instructions specific to external IRB initial submissions (Kerberos ID and password required).
The study team must submit study modifications and continuing reviews to the External Review Unit via Research Navigator. This is required for institutional review, tracking, and documentation purposes. Institutional clearance from the NYU Grossman School of Medicine’s External Review Unit must be obtained before being submitted to the selected external IRB. Note that modifications including changes in personnel and research locations must be cleared by the External Review Unit even if these changes are not reviewed by the external IRB.
It is required that you notify the External Review Unit if you are closing a study reviewed by an external IRB. Please email notification and documentation of the study closure to firstname.lastname@example.org.
View the Research Navigator Submit Modifications and Continuation Submission Guide (Kerberos ID and password required).